Skip to main content
SpringerLink
Log in

Preventive effects of Escherichia coli strain Nissle 1917 with different courses and different doses on intestinal inflammation in murine model of colitis

  • Original Research Paper
  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract

Objective

To analyze the in vivo effect of Escherichia coli Nissle 1917 (EcN) with different courses and different doses to Sprague–Dawley rats with trinitrobenzene sulfonic acid (TNBS)-induced colitis.

Methods

The probiotic was orally administered with different courses of treatment (with or without pre-administration) and different doses (107–109 CFU/day) to Sprague–Dawley rats with TNBS-induced colitis. Therapeutic effects, levels of cytokine in serum, mRNA and protein expression were analyzed.

Results

Oral EcN administration after TNBS-induced improved colitis dose dependently. In parallel, a reduction of disease activity index and colonic MPO activity together with a decreased level of TNF-α and a trend of increased IL-10 expression was detected. Pre-administration of 107 CFU/day EcN to TNBS-treated rats resulted in a significant protection against inflammatory response and colons isolated from these rats exhibited a more pronounced expression of ZO-1 than the other groups. In the group of pre-administration of 109 CFU/day, the condition was not improved but deteriorated.

Conclusions

This study convincingly demonstrates that pre-administration of probiotic EcN with low dose is able to protect colitis of rats and mediate up-regulation of ZO-1 expression, but long-term of high-dose EcN may do harm to colitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106(Suppl 1):S2–25 quiz S26.

    Article  CAS  PubMed  Google Scholar 

  2. Wang Y, Ouyang Q. Ulcerative colitis in China: retrospective analysis of 3,100 hospitalized patients. J Gastroenterol Hepatol. 2007;22:1450–5.

    Article  PubMed  Google Scholar 

  3. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–17.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Huys G, Vanhoutte T, Vandamme P. Application of sequence-dependent electrophoresis fingerprinting in exploring biodiversity and population dynamics of human intestinal microbiota: what can be revealed? Interdiscip Perspect Infect Dis. 2008;2008:597603.

    PubMed Central  PubMed  Google Scholar 

  5. Lefkovitz AL, Zarowitz BJ. It’s a microscopic world after all: prebiotics, probiotics, and synbiotics. Geriatr Nurs. 2013;34:323–5.

    Article  PubMed  Google Scholar 

  6. McNabb B, Isakow W. Probiotics for the prevention of nosocomial pneumonia: current evidence and opinions. Curr Opin Pulm Med. 2008;14:168–75.

    Article  PubMed  Google Scholar 

  7. Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, et al. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle, a novel effect of a probiotic bacterium. Infect Immun. 1917;2004(72):5750–8.

    Google Scholar 

  8. Tannock GW, Munro K, Harmsen HJ, Welling GW, Smart J, Gopal PK. Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol. 2000;66:2578–88.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Lammers KM, Helwig U, Swennen E, Rizzello F, Venturi A, Caramelli E, et al. Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am J Gastroenterol. 2002;97:1182–6.

    Article  CAS  PubMed  Google Scholar 

  10. Malin M, Suomalainen H, Saxelin M, Isolauri E. Promotion of IgA immune response in patients with Crohn’s disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab. 1996;40:137–45.

    Article  CAS  PubMed  Google Scholar 

  11. Schultz M, Linde HJ, Lehn N, Zimmermann K, Grossmann J, Falk W, et al. Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J Dairy Res. 2003;70:165–73.

    Article  CAS  PubMed  Google Scholar 

  12. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol. 1999;276:G941–50.

    CAS  PubMed  Google Scholar 

  13. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580–91.

    Article  CAS  PubMed  Google Scholar 

  14. Henker J, Laass M, Blokhin BM, Bolbot YK, Maydannik VG, Elze M, et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr. 2007;166:311–8.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Henker J, Laass MW, Blokhin BM, Maydannik VG, Bolbot YK, Elze M, et al. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr Infect Dis J. 2008;27:494–9.

    Article  PubMed  Google Scholar 

  16. Fric P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol. 2003;15:313–5.

    Article  PubMed  Google Scholar 

  17. Schultz M. Clinical use of E. coli Nissle, in inflammatory bowel disease. Inflamm Bowel Dis. 1917;2008(14):1012–8.

    Google Scholar 

  18. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Hoffmann JC, Zeitz M, Bischoff SC, Brambs HJ, Bruch HP, Buhr HJ, et al. Diagnosis and therapy of ulcerative colitis: results of an evidence based consensus conference by the German society of digestive and metabolic diseases and the competence network on inflammatory bowel disease. Z Gastroenterol. 2004;42:979–83.

    Article  CAS  PubMed  Google Scholar 

  20. Malchow HA. Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol. 1997;25:653–8.

    Article  CAS  PubMed  Google Scholar 

  21. Gronbach K, Eberle U, Muller M, Olschlager TA, Dobrindt U, Leithauser F, et al. Safety of probiotic Escherichia coli strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host. Infect Immun. 2010;78:3036–46.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Behnsen J, Deriu E, Sassone-Corsi M, Raffatellu M. Probiotics: properties, examples, and specific applications. Cold Spring Harb Perspect Med. 2013;3:a010074.

    Article  PubMed  Google Scholar 

  23. Camuesco D, Comalada M, Rodriguez-Cabezas ME, Nieto A, Lorente MD, Concha A, et al. The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br J Pharmacol. 2004;143:908–18.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Bell CJ, Gall DG, Wallace JL. Disruption of colonic electrolyte transport in experimental colitis. Am J Physiol. 1995;268:G622–30.

    CAS  PubMed  Google Scholar 

  25. Arribas B, Rodriguez-Cabezas ME, Camuesco D, Comalada M, Bailon E, Utrilla P, et al. A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice. Br J Pharmacol. 2009;157:1024–33.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Altenhoefer A, Oswald S, Sonnenborn U, Enders C, Schulze J, Hacker J, et al. The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol. 2004;40:223–9.

    Article  CAS  PubMed  Google Scholar 

  27. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004;126:1620–33.

    Article  PubMed  Google Scholar 

  28. Scholmerich J. Inflammatory bowel disease: pandora’s box, present and future. Ann N Y Acad Sci. 2006;1072:365–78.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by grants from the National Scientific Support Project (nos. 20100202, 02012BAI06B03 and BSW11J013), National Natural Science Foundation of China (Nos. 81322037 and 81370504) and National Excellent Doctoral Dissertation of PR China (No. 201182).

Conflict of interest

There are no conflicts of interest to disclose in this paper.

Author information

Authors and Affiliations

  1. State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, 17 Changle Western Road, Xi’an, Shaanxi, 710032, People’s Republic of China

    Sumei Sha, Bin Xu, Ni Wei, Jian Liu & Kaichun Wu

  2. No. 174 Hospital of People’s Liberation Army, Xiamen, Fujian, 361000, People’s Republic of China

    Bin Xu

  3. Department of Gastroenterology, Xi’an No.1 Hospital, Xi’an, Shaanxi, 710002, People’s Republic of China

    Xiangyun Kong

Authors
  1. Sumei Sha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bin Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiangyun Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ni Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jian Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kaichun Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kaichun Wu.

Additional information

Responsible Editor: Liwu Li.

Sumei Sha, Bin Xu, and Xiangyun Kong contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sha, S., Xu, B., Kong, X. et al. Preventive effects of Escherichia coli strain Nissle 1917 with different courses and different doses on intestinal inflammation in murine model of colitis. Inflamm. Res. 63, 873–883 (2014). https://doi.org/10.1007/s00011-014-0761-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00011-014-0761-1

Keywords

Search

Navigation